Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
late-stage studies evaluating the efficacy and safety of lead candidate, paltusotine, for the treatment of acromegaly. Acromegaly is a rare endocrine disease generally caused by a pituitary adenoma, which is a non-cancerous tumor in the pituitary that secretes growth hormone. The PATHFNDR-2 study is evaluating paltusotine, an oral SST2 agonist, in participants with acromegaly who are treatment-naïve or not currently receiving medical therapy. Per the data readout, the phase III PATHFNDR-2 study met its primary endpoint, with statistical significance, observing that 56% of patients treated with paltusotine achieved an insulin-like growth factor 1 (IGF-1) level = 1.0 times the upper limit of normal (xULN) compared with those who received placebo (5%). Crinetics also reported that all secondary endpoints met statistical significance. Additionally, CRNX stated that the candidate was overall well tolerated with no serious adverse events in the PATHFNDR-2 study. Management believe
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $54.00 to $55.00. They now have an "outperform" rating on the stock.MarketBeat
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at JMP Securities from $60.00 to $80.00. They now have a "market outperform" rating on the stock.MarketBeat
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Jonestrading from $52.00 to $56.00. They now have a "buy" rating on the stock.MarketBeat
CRNX
Earnings
- 2/28/24 - Miss
CRNX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- CRNX's page on the SEC website